Everything below concerns Plasma half-life. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
The known metal ligands are His, Glu, Asp, or Lys and at least one other residue is required for catalysis, which may play an electrophillic role. Of the known metalloproteases, around half contain an HEXXH motif, which has been shown in crystallographic studies to form part of the metal-binding site. The HEXXH motif is relatively common, but can be more stringently defined for metalloproteases as 'abXHEbbHbc', where 'a' is most often valine or threonine and forms part of the S1' subsite in thermolysin and neprilysin, 'b' is an uncharged residue, and 'c' a hydrophobic residue. Proline is never found in this site, possibly because it would break the helical structure adopted by this motif in metalloproteases.
{\displaystyle {\begin{cases}{\ce {^{244}_{96}Cm ->[{\ce {(\alpha,n)}}] ^{247}_{98}Cf ->[\epsilon][3.11 \ {\ce {h}}] ^{247}_{97}Bk}}\\{\ce {^{244}_{96}Cm ->[{\ce {(\alpha,p)}}] ^{247}_{97}Bk}}\end{cases}}}
Several other Facebook groups with the acronym "DDS" supported Duterte as early as 2011. Among these groups is the Duterte Defense Squad, which was created on July 5, 2011. Other examples include Digong Duterte Supporters-Registered Nurses Group, Duterte's Destiny is to Serve the Country, Digong Duterte Swerte (lit. 'Digong Duterte is (Good) Luck'), and Davsur Duterte Supporters. In 2015, members of these groups urged Duterte to run for president.
Sources: en.wikipedia.org
==== Entrapment of catalytically active noble metal nanoparticles ==== The entrapment of catalytically active noble metals can be accomplished by grafting on functional groups to the unsaturated metal site on MOFs. Ethylenediamine (ED) has been shown to be grafted on the Cr metal sites and can be further modified to encapsulate noble metals such as Pd. The entrapped Pd has similar catalytic activity as Pd/C in the Heck reaction. Ruthenium nanoparticles have catalytic activity in a number of reactions when entrapped in the MOF-5 framework. This Ru-encapsulated MOF catalyzes oxidation of benzyl alcohol to benzaldehyde, although degradation of the MOF occurs. The same catalyst was used in the hydrogenation of benzene to cyclohexane. In another example, Pd nanoparticles embedded within defective HKUST-1 framework enable the generation of tunable Lewis basic sites. Therefore, this multifunctional Pd/MOF composite is able to perform stepwise benzyl alcohol oxidation and Knoevenagel condensation.
==== Metabolism aids ==== Since kitten diets are very high in calories, ingredients must be implemented to ensure adequate digestion and utilization of these calories. Choline chloride is an ingredient that maintains fat metabolism. Biotin and niacin are also active in the metabolism of fats, carbs, and protein. Riboflavin is also necessary for the digestion of fats and carbohydrates. These are the main metabolic aids incorporated into kitten diets to maximize nutrient utilization.
=== Tolerance === A very rapid and strong tolerance, known as tachyphylaxis, develops to the effects of psychedelics with repeated administration. It develops with a single dose and is present within hours to days. Already by the second day, with LSD, there was a 50% decrease in psychoactive effects in one study. Following a few days of repeated administration, or 3 to 4 days in the case of LSD, there is an almost complete absence of effects. The tolerance remains stable thereafter. In one study that gave LSD continuously for up to 84 days, doubling, tripling, and quadrupling the dose was unable to fully overcome the tolerance and restore effects. An abstinence period of 3 to 6 days is required for sensitivity to return and tolerance to fully reset. LSD, psilocybin, and mescaline all show cross-tolerance with each other. Tolerance has been shown to develop to numerous psychedelics in animals and/or humans. Tolerance with psychedelics develops to both their psychoactive effects and their physical effects, such as pupil dilation and tachycardia. As a result of the tolerance, recreational psychedelic users do not use the drugs daily but often show a once-per-week use pattern. Some possible exceptions among psychedelics which may not build tolerance or may develop it much less rapidly include dimethyltryptamine (DMT), ayahuasca (which contains DMT), and 5-MeO-DMT. Similarly, the structurally related dipropyltryptamine (DPT) and diisopropyltryptamine (DiPT) did not show behavioral tolerance in rodents, in contrast to DOI and 2C-T-7.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.